Here's the Top FDA Decision to Watch in 2021

In this video from Motley Fool Live, recorded on Jan. 4, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss the upcoming decision by the Food and Drug Administration (FDA) over whether to approve aducanumab, Biogen's (NASDAQ:BIIB) Alzheimer's disease drug. The FDA's leadership supports the marketing application, but the agency's advisory committee of outside experts voted against the approval, setting up a pivotal moment that could set the stage for the rest of 2021 and beyond.